We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
CANBridge Life Sciences announced that the China Food and Drug Administration (CFDA) has approved the Investigational New Drug (IND) application for a Phase II/III clinical study of lead candidate, CAN008